1)LeRoy EC, et al:Scleroderma(systemic sclerosis);Classification, subsets and pathogenesis. J Rheumatol 15:202-204, 1988
2)Clements PJ, et al:Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheum 22:1281-1285, 1995
3)Kowal-Bielecka O, et al:EULAR recommendations for the treatment of systemic sclerosis:a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 68:620-628, 2009
4)Elizabeth N Le, et al:Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis 70:1104-1107, 2011
5)Rodnan GP, et al:Skin thickness and collagen content in progressive systemic sclerosis(scleroderma)and localized scleroderma. Arthritis Rheum 22:130-140, 1979
6)Clements PJ, et al:Skin thickness score in systemic sclerosis;An assessment of intraobserver variability in 3 independent studies. J Rheum 20:1892-1896, 1993
7)Clements PJ, et al:Inter and intraobserver variability of total skin thickness score(modified Rodnan TSS)in systemic sclerosis. J Rheum 22:1281-1285, 1995
8)Black CM:Measurement of skin involvement in scleroderma. J Rheumatol 22:1217-1219, 1995
9)Clements PJ, Medsger TA Jr:Organ involvement;Skin. Frust DE, Clements PJ(ed):Systemic sclerosis, 1st ed, pp389-407, Williams & Wilkins, 1995
10)Medsger TA Jr:Syetmic sclerosis (scleroderma);Clinical aspects. Koopman WJ(ed):Arthritis and Allied Conditions, 13th ed, p1433-1464, Lea & Febiger, 1997